Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

2.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

3.

EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk

4.

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

5.

Gene therapy for glioblastoma is effectively created by researchers.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot